Amgen to Acquire Celgene’s Otezla (apremilast) for $13.4B

 Amgen to Acquire Celgene’s Otezla (apremilast) for $13.4B

Amgen to Acquire Celgene’s Otezla (apremilast) for $13.4B

Shots:

  • Amgen to acquire Otezla for $13.4B in cash and will receive its related intellectual property including patents primarily covering apremilast with all assets and liabilities related to Otezla along with Celgene’s employees associated with the Otezla
  • BMS to divest Otezla in order to get regulatory approval for its pending Celgene merger. The closing of the acquisition of Otezla is contingent on FTC’s blessing on the BMS & Celgene’s pending merger, its closing and the satisfaction of other closing conditions. BMS is expected to complete its pending merger in H2’19
  • Otezla is a selective PDE4 inhibitor, inhibiting the production of TNF-alpha from human rheumatoid synovial cells and is an approved therapy for mod. to sev. plaque psoriasis for whom phototherapy or systemic therapy is appropriate

Click here to­ read full press release/ article | Ref: BMS | Image: Quape

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post